ENVALITH
株式会社Ubicomホールディングス logo

Ubicom Holdings, Inc.

3937・Standard Market・Information & Communication

Official website
株式会社Ubicomホールディングス logo
Ubicom Holdings, Inc.3937

Business

Ubicom Holdings, Inc. is composed of two segments: the Medical Business, whose core offering is the "Mighty series" of medical claim inspection software for healthcare institutions, and the Technology Consulting Business, which provides offshore development and IT consulting leveraging its bases in the Philippines and China. The Medical Business serves over 22,912 medical institutions as customers and has established a highly profitable subscription-based model. The Technology Consulting Business targets domestic and international global companies as its main customers and delivers system development services through a multi-site structure spanning Japan, the Philippines, and China. Consolidated net sales for FY2026 (ending March 2026) were ¥5,993 million.

Business Model

The Medical Business is centered on subscription licenses for medical claims review software, accumulating recurring revenue while capturing demand from medical fee schedule revisions and medical DX initiatives. The segment profit margin is extremely high at 62.9%. The Technology Consulting Business leverages bilingual engineers at its Philippine subsidiary to provide offshore and onshore development, offering person-month-based services to major clients such as IBM, while advancing a shift toward an AI-driven, high-value-added model.

Company Strengths

The number of users in the Medical Business reached 22,912, achieving a segment profit margin of 62.9% through the subscription model of its flagship products "MightyChecker® EX" and "Mighty QUBE® Hybrid." In FY2026 (ending March 2026), segment revenue continued to grow steadily, increasing 13.1% year-on-year to ¥1,949 million, with segment profit up 8.7% year-on-year to ¥1,227 million.

The predecessor of the Philippine subsidiary was established in 1993 and has approximately 30 years of development track record. The in-house training center "ACTION" conducts intensive 5-to-6-month training programs for new hires, systematically cultivating bilingual, highly skilled IT engineers. In 2026, the company received the "Top Supplier Recognition Program Award" from Lenovo, with its quality and process management receiving international recognition.

In May 2023, the company concluded an IBM Strategic Partnership Agreement with IBM Japan, promoting the establishment of an AI-Driven Development (Utilizing watsonx) framework. In the Medical Business, the company made ISM Co., Ltd. a wholly owned subsidiary in 2025, and in April 2026 made Radiance Ware Co., Ltd. (with approximately 475 customers) a subsidiary, steadily executing its M&A strategy.

ENVALITH's Perspective

In FY2026 (ending March 2026), revenue declined to ¥5,993 million (down 5.5% year on year), marking a return to negative growth. The Medical Business remained solid with revenue of ¥1,949 million (up 13.1% year on year) and segment profit of ¥1,227 million (up 8.7% year on year), but the Technology Consulting Business fell sharply, with revenue of ¥4,043 million (down 12.4% year on year) and segment profit of ¥431 million (down 23.4% year on year), dragging down the company as a whole. This is attributed primarily to strategic curtailment of small-scale order intake amid the structural shift toward AI-Driven Development, but the timing of realizing monetization from this shift needs to be monitored.

In FY2026 (ending March 2026), the company made ISM Co., Ltd. a consolidated subsidiary (recording a gain on negative goodwill of ¥2 million), and as a subsequent event, acquired Radiance Wear Co., Ltd. for ¥649 million (effective April 1, 2026). Radiance Wear has approximately 475 clients, and its earnings contribution is expected to begin from FY2027 (ending March 2027). The company plans to carry out a cumulative total of 8 to 10 M&A deals between 2025 and 2030, and whether the incorporation of agency networks progresses as planned in generating cross-selling effects and transitioning to a direct sales model will be the key evaluation axis for mid- to long-term growth. It should also be noted that ISM's low profit margin (a characteristic of the agency business) has temporarily lowered the overall profit margin of the Medical Business.

The earnings forecast for FY2027 (ending March 2027) calls for revenue of ¥7,383 million (up 23.2% year on year) and operating profit of ¥1,511 million (up 15.9% year on year), which would mark a record-high profit. This forecast is premised on the consolidation contribution from Radiance Wear and the conversion of AI-Driven Development projects into full-scale production engagements. On the other hand, uncertainty remains as to whether PoC projects in the Technology Consulting Business can transition to the full development phase. In addition, the dividend forecast for FY2027 (ending March 2027) is stated as "undetermined," raising the possibility of a change from the FY2026 (ending March 2026) payout ratio of 54.4% (¥40 per share), and clarification of the shareholder return policy is required.

Growth Strategy

Multi-layering of the medical DX platform, agency M&A, and evolution of the earnings structure through the shift to AI-Driven Development

In addition to expanding sales of the flagship products centered on "MightyChecker® EX" and "Mighty QUBE® Hybrid," the new product "MightyChecker® Cloud X" was released from April 2026. The company is expanding its user base by extending into small hospitals in addition to clinics, accelerating the accumulation of recurring revenue.

Between 2025 and 2030, the company is pursuing a cumulative total of 8-10 M&A deals targeting community-based medical network companies with sales scales ranging from several million yen to ¥1.0 billion. ISM was made a subsidiary in FY2026 (ending March 2026), and Radiance Ware Inc. (acquisition cost ¥649 million, approximately 475 customers) was made a subsidiary in April 2026, aiming to strengthen cross-selling and the direct-sales model.

The company is expanding the Medical Cloud Service "SonaM" and the "Insurance Knowledge Platform," an operational efficiency solution for the insurance industry. Implementation at Asahi Mutual Life Insurance Company began in January 2026, expanding the cumulative number of adopting companies to 5. The company aims to penetrate the entire insurance industry through cross-selling of additional options and as a new subscription-type offering.

With IBM's AI platform (watsonx) as the core infrastructure, the company is ramping up strategic investment in establishing an AI center and developing human capital. In Q4 of FY2026 (ending March 2026), the company is advancing the acquisition and verification of PoC projects, aiming to transition to the full development phase for large-scale enterprise projects in the finance, manufacturing, medical, and energy sectors. The plan is to shift to the implementation phase from FY2027 (ending March 2027) and accelerate monetization in earnest.

The company implemented management restructuring at the Philippine subsidiary, transitioning to a structure led by the Japan headquarters, along with cost structure reforms. Through the expansion of direct-contract projects in the healthcare/life sciences sector, centered on the United States, the company is promoting diversification of revenue and reducing dependence on Japan. In FY2026 (ending March 2026), the Philippine subsidiary's sales were held to ¥2,850 million (down 2.5% year on year), while operating profit increased 28.9% year on year.

Last updated: July 19, 2026